4 completed, 2 terminated, 1 withdrawn. 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Completed 4, Terminated 2, Withdrawn 1 |
Follow Elan Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) Methylprednisolone, Prednisolone - Immune Reconstitution Inflammatory Syndrome, Leukoencephalopathy, Progressive Multifocal | Phase 4 | Terminated | Biogen | 3 | 2010-09-01 | 2014-09-05 |
| A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients BG00002 (natalizumab) - Relapsing Remitting Multiple Sclerosis (RRMS) | Phase 4 | Completed | Biogen | 224 | 2009-08-01 | 2017-03-21 |
| Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy natalizumab - Crohn's Disease | Phase 4 | Withdrawn | Biogen | 2008-12-01 | 2016-06-16 | |
| A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State Natalizumab - Multiple Sclerosis | Phase 4 | Completed | Biogen | 20 | 2008-11-01 | 2015-02-10 |
| Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease natalizumab - Crohn's Disease | Phase 4 | Completed | Biogen | 2000 | 2002-07-01 | 2016-06-16 |
| Open-label Adjunctive Zonisamide for Bipolar Disorder zonisamide - Bipolar Disorders | Phase 4 | Terminated | Elan Pharmaceuticals | 20 | 2002-07-01 | 2015-12-14 |
| Cefepime vs. Ceftriaxone to Treat Nursing Home-Acquired Pneumonia cefepime, ceftriaxone - Pneumonia | Phase 4 | Completed | CPL Associates | 69 | 2002-03-01 | 2007-10-31 |
Crohn Disease (2) · Bipolar Disorder (1) · Immune Reconstitution Inflammatory Syndrome (1) · Leukoencephalopathy, Progressive Multifocal (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Relapsing-Remitting (1) · Pneumonia (1)
Natalizumab (4) · Cefepime (1) · Ceftriaxone (1) · Methylprednisolone (1) · Methylprednisolone Hemisuccinate (1) · Prednisolone (1) · Zonisamide (1)
United States (4) · Belgium (1) · Germany (1) · Mexico (1) · Poland (1) · Romania (1) · Saudi Arabia (1) · Ukraine (1)